RSV, Canada and Moderna
Canada approves Moderna's RSV vaccine for those age 60 and older, company says
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus, or RSV, in adults 60 years and older, making it the country's first authorized mRNA-based shot for the condition. Health Canada has approved the ...
Moderna Sales Get Lift From Early Nod
Barclays lowered the firm’s price target on Moderna (MRNA) to $111 from $125 and keeps an Overweight rating on the shares. The ...
Moderna Inc.’s stock jumped 5% early Thursday, after the company’s third-quarter earnings showed an unexpected profit and ...
Moderna reported earnings that exceeded expectations due to effective cost management but still has challenges related to its ...
Bank of America Securities analyst Alec Stranahan reiterated a Hold rating on Moderna (MRNA – Research Report) today and set a price ...
(Reuters) -Vaccine maker Moderna's chief executive officer Stephane Bancel will vacate his role as the company's chief ...
Stephane Bancel is stepping down as chief commercial officer of Moderna Inc., according to a person familiar with the matter.
Moderna ( (MRNA) ) has released its Q3 earnings. Here is a breakdown of the information Moderna presented to its investors. Moderna, Inc. is a ...
Sales of Moderna’s COVID-19 shot exceeded expectations, but the company’s launch of its new RSV vaccine has started slowly.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback